Filters: keyword is Humans [Clear All Filters]
- 2009
Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex,
Anesthesiology, vol. 110, no. 1, pp. 95-105. DOI
- 2008
Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model,
J Psychiatr Res, vol. 42, no. 14, pp. 1189-97. DOI
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy,
J Psychiatr Res, vol. 42, no. 12, pp. 1000-9. DOI
Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients,
Clin Pharmacol Ther, vol. 83, no. 3, pp. 443-51. DOI
Pilot study on the influence of liver blood flow and cardiac output on the clearance of propofol in critically ill patients,
Eur J Clin Pharmacol, vol. 64, no. 3, pp. 329-34. DOI
Prediction of attack frequency in migraine treatment,
Cephalalgia, vol. 28, no. 8, pp. 847-55. DOI
Extensions to the visual predictive check to facilitate model performance evaluation,
J Pharmacokinet Pharmacodyn, vol. 35, no. 2, pp. 185-202. DOI
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research,
Trends Pharmacol Sci, vol. 29, no. 4, pp. 186-91. DOI
Relevance of absorption rate and lag time to the onset of action in migraine,
Clin Pharmacokinet, vol. 47, no. 2, pp. 139-46. DOI
- 2007
Analysis of responses in migraine modelling using hidden Markov models,
Stat Med, vol. 26, no. 22, pp. 4163-78. DOI
Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks,
Antimicrob Agents Chemother, vol. 51, no. 10, pp. 3720-5. DOI
Allometric scaling of pharmacodynamic responses: application to 5-Ht1A receptor mediated responses from rat to man,
Pharm Res, vol. 24, no. 11, pp. 2031-9. DOI
Application of the convection-dispersion equation to modelling oral drug absorption,
Bull Math Biol, vol. 69, no. 1, pp. 181-95. DOI
Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers,
Clin Pharmacol Ther, vol. 81, no. 1, pp. 50-8. DOI
Current issues relating to drug safety especially with regard to the use of biomarkers: a meeting report and progress update,
Eur J Pharm Sci, vol. 30, no. 2, pp. 107-12. DOI
Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine,
Clin Pharmacokinet, vol. 46, no. 5, pp. 433-47. DOI
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis,
Annu Rev Pharmacol Toxicol, vol. 47, pp. 357-400. DOI
Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers,
Clin Pharmacokinet, vol. 46, no. 11, pp. 965-80. DOI
- 2006
A model-based approach to treatment comparison in acute migraine,
Br J Clin Pharmacol, vol. 62, no. 5, pp. 591-600. DOI
Buprenorphine induces ceiling in respiratory depression but not in analgesia,
Br J Anaesth, vol. 96, no. 5, pp. 627-32. DOI
Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery,
Anesthesiology, vol. 104, no. 3, pp. 466-74. DOI
Population pharmacodynamic modelling of lorazepam- and midazolam-induced sedation upon long-term continuous infusion in critically ill patients,
Eur J Clin Pharmacol, vol. 62, no. 3, pp. 185-94. DOI
Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers,
Br J Pharmacol, vol. 148, no. 4, pp. 396-404. DOI
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers,
Anesthesiology, vol. 104, no. 6, pp. 1232-42. DOI
Naloxone reversal of buprenorphine-induced respiratory depression,
Anesthesiology, vol. 105, no. 1, pp. 51-7. DOI


